Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHRM 864 Module 4 > Gout > Flashcards

Gout Flashcards

1
Q

What is gout?

A

inflammatory process in response to crystallization of monosodium urate in articular and non-articular tissues
hyperuricemia - uric acid level > 6.8 mg/dL AND symptomatic (can have hyperuricemia w/o sx or gout, so we don’t treat)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Epidemiology

A

men more likely to be affefcted
individual factors that may influence development of gout: genetics, dietary intake, socioeconomic factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Pathophysiology

A

uric acid is main end product in purine degradation
allantoin is a soluble byproduct from uric acid breakdown
uric acid concentrations influenced by overproduction or underexcretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Hyperuricemia -overproduction

A

regulatory enzyme variability, cytotoxic medications, increase dietary intake of purines, chronic alcohol intake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Hyperuricemia - underexcretion

A

dehydration, insulin resistance, acute alcohol intake, meds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Medications

A

diuretics (loops and thiazides), cytotoxic drugs, salicylates (<2g/day)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Risk factors

A

male, post-menopausal women (estrogen helps with excretion of uric acid), elderly, obesity, diet and alcohol intake, sedentary lifestyle, renal impairment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Acute gouty arthritis presentation

A

acute, inflammatory monoarthritis
podagra - first metatarsal joint often involved
uric acid can deposit elsewhere: fingers or wrist, cartilage or tendons, kidneys
s/sx: fever, intense pain, erythema, warmth, edema, and inflammation of affected joints

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Lab tests

A

elevated uric acid > 6.8 mg/dL
WBC > 11,000cell/uL (could be an infection, use to rule out)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Complications

A

tophi - deposits of monosodium urate
nephrolithiasis - kidney stones
gouty nephropathy - acute and chronic kidney disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Diagnosis

A

synovial fluid aspiration (not feasible)
in clinical practice use: monoarticular involvement, previous episodes, rapid onset of pain, swelling, and erythema, risk factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Treatment goals

A

terminate acute attack
prevent recurrent attacks of gouty arthritis
prevent complications associated with chronic deposition or urate crystals in joints and tissues
patient education

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Treatment approach

A

treatment of pain and inflammation (acute tx)
use of urate-lowering therapy to prevent recurrence (chronic treatment)
anti-inflammatory prophylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Non-pharmacologic therapy

A

modification of risk factors over time
applying ice to the affected area to reduce pain
no supplements have shown benefit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pharmacologic therapy for acute treatment

A

NSAIDs, corticosteroids, colchicine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

NSAIDs

A

MOA: inhibits COX1 and 2 and decreases prostaglandin synthesis, thus decreasing inflammation
effective and have minimal toxicity short term

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

NSAIDs meds

A

indomethacin, naproxen, ibuprofen, sulindac
early initiation is key!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

NSAID AEs

A

GI effects, kidney injury, CV effects, CNS effects, bleeding risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Corticosteroids

A

MOA: decreases inflammation by suppression of leukocytes, reverses increased capillary permeability, and suppresses the immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Oral corticosteroids

A

methylprednisolone
prednisone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

IM corticosteroids

A

triamcinolone
methylprednisolone
then follow with anti-inflammatory agent (NSAID, PO corticosteroid) b/c might have rebound pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Intra-articular corticosteroids

A

triamcinolone
then follow with anti-inflammatory agent (NSAID, PO corticosteroid)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Corticosteroid tapering

A

prednisone: 0.5mg/kg daily for 5-10 days followed by abrupt discontinuation
0.5mg/kg daily for 2-5 days followed by taper for 7-10 days

24
Q

Corticosteroid AEs

A

increased BG, anxiety and restlessness, GI upset, insmonia, fluid retention, BP elevation

25
Q

Corticosteroid considerations

A

taper PO courses, limit treatment duration, increased risk of GI bleed and peptic ulcer disease, close monitoring of diabetes, avoid IA injection if suspect infection

26
Q

Colchicine

A

MOA: disrupts cytoskeletal functions by inhibiting beta-tubulin polymerization into microtubules, thus preventing the activation, degranulation, and migration of neutrophils associated with gout sx

27
Q

Colchicine recommended to administer

A

within 24hrs of acute attack (if longer, tons of WBCs + neutrophils already there and working)
oral capsule, tablet, and solution

28
Q

Colchicine dosing

A

day 1: 1.2mg PO once, then 0.6mg one hour later
day 2+: 0.6 mg BID until attack resolves

29
Q

Colchicine AEs

A

N/V/D
neutropenia, axonal neuromyopathy

30
Q

Colchicine renal dose adjustments

A

CrCl >/= 30 mL/min: no adjustment required
CrCl < 30 mL/min: 1.2mg at onset, 0.6 mg 1 hr later (once) do NOT follow up with 0.6mg BID after
dialysis: single 0.6mg dose
treatment course should be repeated no more than once every 2 weeks

31
Q

Colchicine inadequate initial response

A

<50% improvement in pain in 24hrs: switch agents, add a 2nd recommended agent - try to avoid NSAIDs with PO corticosteroids together

32
Q

Colchicine clinical pearl

A

pill-in-pocket method: pts who can recognize gout sx onset use aborptive agents like NSAIDs or colchicine
recommended to decrease time to treatment for adequate pain control and response
do NOT use in pts who have frequent attacks

33
Q

Chronic gout management - nonpharmacologic therapy

A

weight loss if overweight/obese
dietart approaches to stop HTN - may lower uric acid ~1mg/dL; DASH diet, avoid foods high in saturated fats and sweetened beverages/foods
alcohol restriction
limit restriction of purine-rich foods: high fructose corn syrup, organ meats and seafood

34
Q

Chronic gout management: urate lowering therapy - indications to start

A

frequent gout flares >/= 2 per year; >/= 1 tophus; radiographic evidence of damage attributable to gout; > 1 prior flare, but infrequent (< 2/yr); pts experience 1st flare in the presence of 1 of the following: CKD stage 3-5, uric acid > 9mg/dL, urolithiasis

35
Q

Who is not a candidate for ULT?

A

asymptomatic hyperuricemia with no prior gout flare or tophi
1st gout attack without risk factors

36
Q

ULT initiation/duration of therapy

A

initiation: either wait 2 weeks after acute attack or initiate during an acute attack
duration: indefinitely!

37
Q

ULT monitoring

A

serum uric acid at baseline and periodically
treat to target of serum uric acid < 6mg/dL

38
Q

Chronic gout pharmacologic therapy

A

1st line: xanthine oxidase inhibitors
2nd line: uricosurics
3rd line: uricase agents

39
Q

Xanthine oxidase inhibitors MOA

A

reduces uric acid by impairing the ability of xanthine oxidase to convert hypoxanthine to xanthine and therefore to uric acid (inhibits enzyme that forms uric acid)

40
Q

Xanthine oxidase inhibitor meds

A

allopurinol: titrate every 2-4 wks in </=100 increments as needed to achieve uric acid < 6mg/dL
febuxostat

41
Q

Allopurinol renal impairment

A

eGFR > 60: no adjustment
eGFR </= 60: initial dose 50 mg
titrate slowly and in small increments (can still achieve higher doses)

42
Q

Allopurinol AEs

A

skin rash, HA, urticaria, hepatotoxicity, hypersensitivity rxn - stevens johnson syndrome and toxic epidermal necrolysis (risk factors = female, age >60, high initial doses, CKD, CV disease) test for HLA-B*5801 allele to see if + in pts with southeast asian or african decent

43
Q

Allopurinol monitoring and counseling

A

monitor: uric acid q2-5wks while titrating, every 6mo when stable; renal fx; LFTs
counsel: drink plenty of fluids, take this med even when you do not have gout sx!

44
Q

Febuxostat

A

black box warning: increased CV mortality
this med reserved for pts unable to tolerate allopurinol
AEs: nausea, arthralgias, rash
renal dosing adjusment

45
Q

Uricosuric drugs MOA

A

increase renal clearance of uric acid by inhibiting post-secretory renal proximal tubular reabsorption of uric acid

46
Q

Uricosuric drug

A

probenecid: titrate q1-2wks

47
Q

Probenecid

A

AEs: GI irritation, rash, urolithiasis (contraindicated in pts with history)
cautions: G6PD deficiency (increased risk of hemolytic anemia), not recommended in eGFR < 60

48
Q

Uricase agents MOA

A

recombinant form of urate-oxidase enzyme (uricase) converts uric acid to the more soluble metabolite, allantoin (able to be excreted)

49
Q

Uricase agents med

A

pegloticase - used in severe gout and hyperuricemia: >/=3 gout flares within 18mo, >/=1 tophi, joint damage due to gout
IV infusion (infused over 2hrs every 2wks)

50
Q

Pegloticase

A

black box warning: anaphylaxis and infusion related rxns; G6PD deficiency associated hemolysis and methemoglominemia
AEs: constipation, N/V, chest pain, nasopharyngitis
pearls: immunogenicity: pt may develop antibodies that result in lack of efficacy of drug

51
Q

Other ULT meds

A

fenofibrate
losartan

52
Q

Fenofibrate

A

MOA: increases clearance of hypoxanthine and xanthine
NOT recommended to switch hyperlipidemia agents for gout benefits

53
Q

Losartan

A

MOA: inhibits tubular reabsorption of uric acid and increases urinary excretion; reduces stone formation by alkalinizing the urine
preferred agent in pts with gout AND HTN

54
Q

Gout attack prophylaxis

A

use when initiating ULT –> goal to decrease incidence of gout attacks –> duration recommended for 1st 3-6mo of ULT initiation

55
Q

Gout attack prophylaxis therapy

A

NSAIDs, prednisone, colchicine
duration: during initiaiton of ULT, 3-6mo or longer if indicated

56
Q

Prophylaxis: colchicine dosing

A

CrCl >/=30 mL/min: 0.6 mg once or twice daily (lower than acute dosing)
CrCl < 30 mL/min: consider alternate therapy, if not able to: 0.3mg daily, if on dialysis then 0.3mg twice weekly

PHRM 864 Module 4 (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions